Stimulace vagusového nervu pro středně těžkou až těžkou revmatoidní artritidu (RESET-RA)
Stimulace vagusového nervu pomocí systému SetPoint pro středně těžkou až těžkou revmatoidní artritidu: Studie RESET-RA
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Mesa, Arizona, Spojené státy, 85210
- Arizona Arthritis ans Rheumatology Research, PPLC
-
Phoenix, Arizona, Spojené státy, 85037
- Arizona Arthritis Rheumatology & Research, PLLC
-
Tucson, Arizona, Spojené státy, 85704
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Covina, California, Spojené státy, 91722
- Medvin Clinical Research
-
Upland, California, Spojené státy, 91786
- Inland Rheumatology Clinical Trials
-
Whittier, California, Spojené státy, 90602
- Medvin Clinical Research
-
-
Colorado
-
Fort Collins, Colorado, Spojené státy, 80528
- The Arthritis & Rheumatology Clinic of Northern Colorado
-
-
Connecticut
-
Stamford, Connecticut, Spojené státy, 06905
- Stamford Therapeutics Consortium
-
-
Delaware
-
Lewes, Delaware, Spojené státy, 19958
- Delaware Arthritis
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- Arthritis & Rheumatic Disease Specialties
-
Avon Park, Florida, Spojené státy, 33825
- HARAC Research Corporation
-
Boynton Beach, Florida, Spojené státy, 33472
- RecioMed Clinical Research Network, Inc.
-
Clearwater, Florida, Spojené státy, 33765
- Bay Area Rheumatology
-
Plantation, Florida, Spojené státy, 33324
- IRIS Research and Development
-
-
Georgia
-
Augusta, Georgia, Spojené státy, 30912
- Augusta University
-
Lawrenceville, Georgia, Spojené státy, 30044
- Parris and Associates Rheumatology
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
Willowbrook, Illinois, Spojené státy, 60527
- Willow Rheumatology and Wellness PLLC
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
-
-
Michigan
-
Lansing, Michigan, Spojené státy, 48910
- June DO, PC
-
-
Minnesota
-
Eagan, Minnesota, Spojené státy, 55121
- Saint Paul Rheumatology, P.A.
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64151
- Kansas City Physician Partners
-
St Louis, Missouri, Spojené státy, 63122
- West County Rheumatology
-
-
Nebraska
-
Lincoln, Nebraska, Spojené státy, 68516
- Physician Research Collaboration, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87102
- Albuquerque Center for Rheumatology
-
-
New York
-
Babylon, New York, Spojené státy, 11702
- Long Island Regional Arthritis & Osteoporosis Care
-
-
North Carolina
-
Charleston, North Carolina, Spojené státy, 28202
- Arthritis & Osteoporosis Consultants Of The Carolinas
-
Charlotte, North Carolina, Spojené státy, 28210
- DJL Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73103
- Health Research of Oklahoma, PLLC
-
Oklahoma City, Oklahoma, Spojené státy, 73116
- Rheumatology Associates of Oklahoma
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18103
- Lehigh Valley Health Network
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- University of Pennsylvania Medical Center
-
-
Texas
-
Allen, Texas, Spojené státy, 75013
- Arthritis & Rheumatology Research Institute, PLLC
-
Austin, Texas, Spojené státy, 78745
- Tekton Research
-
Austin, Texas, Spojené státy, 78717
- Austin Regional Clinic
-
Austin, Texas, Spojené státy, 78746
- Central Texas Rheumatology Associates
-
Colleyville, Texas, Spojené státy, 76034
- Precision Comprehensive Clinical Research Solutions
-
Houston, Texas, Spojené státy, 77043
- Biopharma Informatic
-
Mesquite, Texas, Spojené státy, 75150
- Southwest Rheumatology Research LLC
-
San Antonio, Texas, Spojené státy, 78229
- Clinical Trials of Texas, Inc
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22033
- Annapolis Rheumatology
-
-
Washington
-
Bothell, Washington, Spojené státy, 98021
- Sound Clinical Research, LLC
-
-
West Virginia
-
Morgantown, West Virginia, Spojené státy, 26506
- West Virginia University
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- 22-75 years of age at screening
- Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
- Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
- Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12
Exclusion Criteria:
- Untreated or poorly controlled psychiatric illness or history of substance abuse
- Significant immunodeficiency due to underlying illness
- History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
- Clinically significant cardiovascular disease
- Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
- Uncontrolled fibromyalgia
- History of left or right carotid surgery
- History of unilateral or bilateral vagotomy, partial or complete splenectomy
- Recurrent vasovagal syncope episodes
- Current, regular use of tobacco products
- Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Treatment
Active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Ostatní jména:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Ostatní jména:
Active stimulation for 1 min once per day |
|
Falešný srovnávač: Control
Non-active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Ostatní jména:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Ostatní jména:
Non-active stimulation for 1 min once per day |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
the American College of Rheumatology (ACR) 20 Response
Časové okno: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Časové okno: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 A subject is considered having a moderate treatment response if:
A subject is considered having a good treatment response if: • DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2 |
Week 12
|
|
DAS28-CRP Response (MCID -1.2) at Week 12
Časové okno: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline. DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 |
Week 12
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Časové okno: Week 12
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 12
|
|
ACR20 Response at Week 12 From Day 0
Časové okno: Week 12
|
Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL). |
Week 12
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Bone Erosion Progression, All Completers
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers With Erosive Phenotype
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Change in Erosion Score, All Completers
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers With Erosive Phenotype
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Synovitis Score, All Completers
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers With Erosive Phenotype
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Osteitis Score, All Completers
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers With Erosive Phenotype
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Časové okno: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Časové okno: Week 12
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 12
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission
Časové okno: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Časové okno: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Časové okno: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Časové okno: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Časové okno: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Časové okno: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Časové okno: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Časové okno: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Časové okno: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Časové okno: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Časové okno: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Časové okno: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Časové okno: Week 24
|
Patients were asked a question about whether they would recommend the SetPoint System to family and friends |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Časové okno: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Časové okno: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Časové okno: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Časové okno: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Časové okno: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Časové okno: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Časové okno: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Časové okno: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Časové okno: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Časové okno: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Časové okno: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Časové okno: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Časové okno: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Časové okno: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Časové okno: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Časové okno: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Časové okno: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Časové okno: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Časové okno: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Časové okno: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Mark Richardson, MD PhD, Massachusetts General Hospital
- Vrchní vyšetřovatel: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.
Publikace a užitečné odkazy
Obecné publikace
- Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024 Mar 13;10(1):8. doi: 10.1186/s42234-023-00138-x.
- Tesser JRP, Crowley AR, Box EJ, June JP, Wickersham PB, Valenzuela GJ, Gaylis NB, Lam GKW, Pacheco LA, Ridley DJ, Pinto-Patarroyo GP, Novack SN, Churchill MA, Kohler M, Lee EC, Pando JA, Parris GR, Peterson JR, Shah T, Singhal AK, Vuong V, Levine YA, Evangelista ML, Derosier AA, Curtis JR, Richardson RM, Chernoff D. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nat Med. 2026 Jan;32(1):369-378. doi: 10.1038/s41591-025-04114-7. Epub 2025 Dec 22.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- SPM-020
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
No sharing data is planned.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .